MUC16 and ovarian carcinoma: However, the early-stage shift was demonstrated as 37.8%, 23%, and 24% in the annual multimodal screening (MMS) by serum CA-125 interpreted with use of the risk of ovarian cancer algorithm, annual TVU, and no screening groups, respectively, in UKCTOCS trial.